Mucopolysaccharidosis I (MPS I) Registry
Completed · NCT00144794
Conditions: Mucopolysaccharidosis I (MPS I)
At a glance
- Research payments reported, 2025
- $12,939
- U.S. investigators named
- 13
- Sites paid
- 12
- Planned or actual enrollment
- 1,406
About the trial
- Sponsor
- Genzyme, a Sanofi Company
- Dates
- Started 2003-11-20; completion 2024-12-31
- Results posted
- Not yet
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) * To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I * To h…
From ClinicalTrials.gov, last updated 2026-02-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $12,939 in research payments for this study in 2025 (13 payments).
Products named: Aldurazyme
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thomas A. Burrow, MD Medical Genetics · Little Rock, AR
- Raymond Y. Wang, MD Pediatrics · Orange, CA
- Christopher B. Griffith, M.D. Medical Genetics · Fort Myers, FL
- Roberto T. Zori, MD Medical Genetics · Gainesville, FL
- William Wilcox Medical Genetics · Decatur, GA
- Gabrielle C. Geddes, MD Medical Genetics · Indianapolis, IN
- Mary-alice Abbott, MD Medical Genetics · Worcester, MA
- Anatalia Labilloy, M.D., PH.D., M.P.H. Medical Genetics · Boston, MA
- Chester B. Whitley, MD Pediatrics · Minneapolis, MN
- Debra-lynn E. Day-salvatore, M.D., PH.D. Medical Genetics · New Brunswick, NJ
- Helio F. Pedro, M.D. Internal Medicine · Newark, NJ
- Nancy D. Leslie, M.D. Medical Genetics · Cincinnati, OH
- David M. Finegold, MD Specialist · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cincinnati Children's Hospital Medical Center, OH $7,459
- University of Pittsburgh $1,350
- Saint Peter's University Hospital, NJ $625
- University of South Florida $624
- Arkansas Childrens Hospital $553
- Children's Hospital of Orange County, CA $550
- University of Florida $520
- Hackensack University Medical Center, NJ $425
- Emory University Hospital, GA $270
- Baystate Medical Center, MA $228
- Regents of the University of Minnesota $200
- The Trustees of Indiana University $136
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.